What is Evenity (romosozumab) and what are its indications, dosing schedule, contraindications, side effects, and monitoring requirements for treating osteoporosis in postmenopausal women and men at high fracture risk?

Evenity (Romosozumab): Overview and Clinical Use

Evenity (romosozumab) is a sclerostin inhibitor indicated exclusively for postmenopausal women with severe osteoporosis at high fracture risk, administered as 210 mg subcutaneously monthly for exactly 12 months, but it carries a critical cardiovascular contraindication that must be screened for before initiation. 1

What is Evenity?

Romosozumab is a humanized monoclonal antibody that works through a unique dual mechanism: it simultaneously increases bone formation while decreasing bone resorption by inhibiting sclerostin, a protein that regulates bone metabolism. 2, 3 This distinguishes it from most osteoporosis medications that only inhibit bone resorption.

Indications

FDA-approved indication: Treatment of osteoporosis in postmenopausal women at high risk for fracture, specifically defined as: 1

• History of osteoporotic fracture, OR
• Multiple risk factors for fracture, OR
• Patients who have failed or are intolerant to other available osteoporosis therapy

Not approved for men - the 2023 ACP guidelines note romosozumab is indicated only for postmenopausal females. 4

Dosing Schedule

• Dose: 210 mg subcutaneously once monthly
• Administration: Requires TWO separate 105 mg injections (two syringes) at each monthly visit
• Sites: Abdomen (avoiding 2 inches around navel), thigh, or outer upper arm
• Duration: Exactly 12 monthly doses - no more, no less 4, 1
• Must be administered by a healthcare provider 1

Critical Dosing Considerations:

The anabolic (bone-building) effect wanes after 12 months, making additional doses ineffective. 4, 1 After completing the 12-month course, patients must transition to an antiresorptive agent (bisphosphonate or denosumab) to maintain gains and prevent rebound fractures. 4, 1

Contraindications

Absolute Contraindications:

1. Myocardial infarction or stroke within the preceding year - this is a BLACK BOX WARNING 1
2. Hypocalcemia - must be corrected before initiating therapy 2

Strong Relative Contraindication:

High cardiovascular risk - The FDA explicitly warns to avoid use in patients with high risk for major cardiovascular events based on FDA Adverse Event Reporting System analysis showing increased major adverse cardiovascular events. 4 Consider whether benefits outweigh risks in patients with other cardiovascular risk factors. 1

Side Effects and Safety Profile

Cardiovascular Risk (Most Critical):

During the first year of treatment, positively adjudicated serious cardiovascular adverse events occurred more frequently with romosozumab (2.5%) versus alendronate (1.9%). 5 If a patient experiences MI or stroke during therapy, discontinue romosozumab immediately. 1

Common Adverse Events:

• Injection site reactions (hypersensitivity and local reactions are increased) 6
• Back pain
• Arthralgia (joint pain)
• Headache
• Muscle cramps and pain 7

Rare but Serious:

• Osteonecrosis of the jaw - rare events observed in trials 5
• Atypical femoral fractures - 2 events in romosozumab-to-alendronate group in ARCH trial 5

Overall serious adverse events were balanced between romosozumab and comparator groups in trials. 5, 6

Monitoring Requirements

Before Initiating:

1. Screen for cardiovascular disease history - specifically MI or stroke in past year
2. Check serum calcium - correct hypocalcemia before starting
3. Ensure adequate vitamin D status
4. Assess fracture risk to confirm high-risk status

During Treatment:

• Supplement with calcium and vitamin D throughout the 12-month course 1
• Monitor for cardiovascular symptoms - chest pain, stroke symptoms
• Watch for injection site reactions
• Monthly clinic visits required for injections

After Completing 12 Months:

Mandatory transition to antiresorptive therapy (bisphosphonate or denosumab) to preserve bone density gains and prevent rebound fractures. 4, 1

Efficacy Data

The ARCH trial demonstrated romosozumab's superiority over alendronate in postmenopausal women with osteoporosis and prior fragility fracture: 5

• 48% lower risk of vertebral fractures at 24 months (6.2% vs 11.9%, P<0.001)
• 27% lower risk of clinical fractures (9.7% vs 13.0%, P<0.001)
• 19% lower risk of nonvertebral fractures (8.7% vs 10.6%, P=0.04)
• 38% lower risk of hip fracture (2.0% vs 3.2%, P=0.02)

Romosozumab increases BMD more than any other osteoporosis agent due to its dual mechanism. 3, 6

Clinical Positioning

According to 2023 ACP guidelines, romosozumab should be reserved for postmenopausal females with primary osteoporosis at very high risk of fracture (conditional recommendation, low-certainty evidence). 4 This means patients with:

• Recent major osteoporotic fracture
• Very high FRAX scores
• Failed bisphosphonate therapy

Bisphosphonates remain first-line for most patients due to better cost-effectiveness and established safety profile. 4

Common Pitfalls to Avoid

1. Do not use beyond 12 months - the anabolic effect disappears
2. Do not skip the transition to antiresorptive therapy - this risks rapid bone loss and rebound fractures
3. Do not use in patients with recent cardiovascular events - this violates the black box warning
4. Do not forget calcium/vitamin D supplementation - hypocalcemia risk
5. Do not assume it's approved for men - it is not, per current guidelines 4